Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Australian & New Zealand Children's Haematology/Oncology Group
ITM Solucin GmbH
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of Southern California
Massive Bio, Inc.
St. Jude Children's Research Hospital
Institut Curie
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Rigshospitalet, Denmark
Miltenyi Biomedicine GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
EMD Serono
St. Jude Children's Research Hospital
Catalysis SL
UNICANCER
Norwegian University of Science and Technology
National Cancer Institute (NCI)
Children's Hospital Los Angeles
City of Hope Medical Center
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Northwestern University
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Northwestern University
University of Texas Southwestern Medical Center
Radiation Therapy Oncology Group
The Methodist Hospital Research Institute
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Duke University
City of Hope Medical Center
Rutgers, The State University of New Jersey
University of California, San Francisco
Dana-Farber Cancer Institute
University of Minnesota
Children's Oncology Group